Bank of Stockton Has $701,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Bank of Stockton boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,151 shares of the company’s stock after purchasing an additional 499 shares during the quarter. Bank of Stockton’s holdings in Novo Nordisk A/S were worth $701,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Stanley Laman Group Ltd. bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $282,000. Weaver Capital Management LLC increased its holdings in Novo Nordisk A/S by 15.3% in the 3rd quarter. Weaver Capital Management LLC now owns 2,298 shares of the company’s stock valued at $274,000 after buying an additional 305 shares during the period. MFA Wealth Advisors LLC increased its holdings in Novo Nordisk A/S by 184.4% in the 3rd quarter. MFA Wealth Advisors LLC now owns 728 shares of the company’s stock valued at $87,000 after buying an additional 472 shares during the period. International Assets Investment Management LLC increased its holdings in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the period. Finally, YHB Investment Advisors Inc. increased its holdings in Novo Nordisk A/S by 11.3% in the 3rd quarter. YHB Investment Advisors Inc. now owns 3,284 shares of the company’s stock valued at $391,000 after buying an additional 334 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 0.5 %

NVO opened at $83.79 on Friday. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $376.02 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 0.90 and a beta of 0.45. The company’s 50 day moving average price is $86.39 and its two-hundred day moving average price is $108.48.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.